CEBPA-bZip mutations are associated with favourable prognosis in de novo AML

October 2021 Science Jolien Blokken

A recent report from the Children’s Oncology Group reported that CCAAT enhancer–binding protein α (CEBPA) basic-region leucine zipper motif (bZip) domain mutations in patients with acute myeloid leukaemia are associated with favourable clinical outcomes, regardless of mono or bi-allelic status. However, co-occurring CSF3R and CEBPA mutations are associated with a high relapse rate and nullify the favourable prognostic impact of CEBPA mutations.

Expert opinion of Prof. Gregor Verhoef, Haematologist, UZ Leuven

Biallelic CCAAT enhancer–binding protein α (CEBPA) mutations are associated with favourable outcomes in acute myeloid leukaemia (AML). CEBPA is a transcription factor coded by an intronless gene located on chromosome 19. CEBPA mutations are detected in 7% to 15% of AML cases. CEBPA plays a pivotal role in normal granulopoiesis. The carboxyterminal moiety of CEBPA has a basic-region leucine zipper motif (bZip). Approximately one-third of CEBPA-mutated AML patients demonstrate a single involved allele, while two-thirds of patients have biallelic mutations. Thus far, studies, mainly in adult patients, supported that only biallelic CEBPA mutations result in improved event-free survival (EFS) and/or overall survival (OS) in AML patients.

Study design

Tarlock et al. evaluated the clinical and biologic implications of CEBPA-basic leucine zipper (CEBPA-bZip) mutations in children and young adults with newly diagnosed AML. CEBPA-bZip mutation status was determined in 2,958 patients treated on consecutive Children’s Oncology Group protocols (NCT00003790, NCT0007174, NCT00372593, NCT01379181). An extensive molecular characterisation of almost two-thirds of the patients (N= 1,862) was performed using next-generation sequencing (NGS) in order to characterise potential co-occurring mutations. Next, CEBPA mutational status was correlated with disease characteristics and clinical outcomes.


CEBPA-bZip mutations were identified in 160 (5.4%) of 2,958 patients. Of those 160 patients, 132 (82.5%) harboured a second CEBPA mutation (CEBPA-double-mutated [CEBPA-dm]) while the remaining 28 patients (17.5%) had a single CEBPA-bZip only mutation. Remarkably, the clinical and laboratory features of the both CEBPA cohorts appeared to be very similar. This was demonstrated by the fact that patients with CEBPA-dm and CEBPA-bZip experienced an identical event-free survival (EFS) of 64%. Furthermore, similar overall survival (OS) rates of 81% and 89%, respectively (p= 0.259) were reported. Of note, these numbers compare favourably to the EFS of 46% and OS of 61% in patients that could be observed in patients with a CEBPA-wild-type (CEBPA-WT) status (both p< 0.001). Transcriptome analysis demonstrated similar expression profiles for patients with CEBPA-bZip and CEBPA-dm. Comprehensive NGS of patients with CEBPA mutations identified co-occurring CSF3R mutations in 13.1% of patients. In addition, GATA2 mutations were reported in 21.5% of patients. Interestingly, patients with dual CEBPA and CSF3R mutations had an EFS of only 17%, as compared to 63% for patients with CEBPA-mutant or CSF3R-WT (p< 0.001). Corresponding relapse rates were 83% vs. 22%, respectively (p< 0.001). In contrast, GATA2 co-occurrence did not seemed have an impact on outcome. It thus far remains unclear whether the results of this paediatric and young adult series be extrapolated to adult patients with AML.


In the largest reported series of children, adolescents, and young adults with AML, biallelic and single CEBPA-bZip mutations demonstrated to have an equally favourable prognostic impact and are thus associated with favourable clinical outcomes, Importantly however, the presence of mutations in the CSF3R gene, together with CEBPA biallelic or single bZIP CEBPA mutations, annuls the favourable impact on patient outcomes and is associated with a high relapse rate.


Tarlock K, Lamble AJ, Wang Y-C, et al. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group. Blood 2021;138(13):1137-47.

Sierre J and Nomdedeu F. CEBPA bZip mutations: just a single shot. Blood 2021;138(13):1091-92.